Non-competing Trop2 nanobody-based radiotheranostics for precision imaging and therapy of pancreatic cancer
Source abstract
Abstract
Pancreatic cancer remains one of the most lethal malignancies, marked by late-stage detection, resistance to conventional therapies, and dismal overall survival. The transmembrane glycoprotein trophoblast cell-surface antigen 2 (Trop2) is frequently upregulated in pancreatic tumors and drives aggressive phenotypes, positioning it as a compelling target for precision oncology interventions. Here, we reported the development of a novel Trop2-specific nanobody-based theranostic pair, [ 68 Ga]Ga-T142 and [ 177 Lu]Lu-T142, capable of both non-invasive molecular imaging and targeted radionuclide therapy. The nanobody T142 was conjugated site-specifically with NODAGA or DOTA chelators, preserving its high Trop2-binding affinity alongside exceptional radiochemical purity and stability. In Trop2-positive pancreatic cancer xenograft models, [ 68 Ga]Ga-T142 demonstrated rapid and high-contrast tumor accumulation, minimal off-target uptake, and pharmacokinetic profiles characteristic of nanobody tracers. Epitope mapping revealed that T142 recognized a region distinct from that targeted by the clinically approved ADC Trodelvy, allowing accurate, interference-free quantification of Trop2 expression during ADC therapy. Longitudinal PET imaging detected early Trop2 downregulation post-ADC treatment, preceding observable tumor shrinkage, and showed superior performance to [ 18 F]FDG in monitoring therapeutic response. On the therapeutic front, [ 177 Lu]Lu-T142 elicited marked tumor regression in Trop2-positive models, while its combination with Trodelvy produced synergistic antitumor effects without significant systemic toxicity. Collectively, these results highlighted [ 68 Ga]Ga-T142 and [ 177 Lu]Lu-T142 as a highly promising Trop2-targeted theranostic platform, with strong potential for precise diagnosis, therapy monitoring, and personalized treatment of Trop2-expressing pancreatic cancer.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Radiopharmaceutical Chemistry and Applications · Cancer Research and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (35)
Show source-provided references
1. Pancreatic cancer: an increasing global public health concern
2. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
3. Cancer statistics, 2025
4. Pancreatic cancer: advances and challenges10.1016/j.cell.2023.02.014 ↗
5. Pancreatic cancer10.1016/S0140-6736(25)00261-2 ↗
6. Therapeutic developments in pancreatic cancer10.1038/s41575-023-00840-w ↗
7. Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance10.1146/annurev-pathmechdis-031621-024600 ↗
8. Leveraging TROP2 antibody-drug conjugates in solid tumors10.1146/annurev-med-071322-065903 ↗
9. Targeting Trop-2 in cancer: recent research progress and clinical application
10. Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial10.1016/j.annonc.2025.01.011 ↗
11. Dowlati A, Chiang AC, Cervantes A, Babu S, Hamilton E, Wong SF, Tazbirkova A, Sullivan IG, van Marcke C, Italiano A, Patel J, Mekan S, Wu T, Waqar SN. Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients with Extensive-Stage SCLC: Results from TROPiCS-03.
12. Sacituzumab govitecan in HR+HER2- metastatic breast cancer: the randomized phase 3 EVER-132-002 trial10.1038/s41591-024-03269-z ↗
13. FDA approval summary: Datopotamab Deruxtecan-dlnk for treatment of patients with unresectable or metastatic, HR-Positive, HER2-Negative breast cancer10.1158/1078-0432.CCR-25-1388 ↗
14. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 Study10.1200/JCO-24-01544 ↗
15. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial10.1016/j.annonc.2021.03.005 ↗
16. Trends in nanobody radiotheranostics10.1007/s00259-025-07077-6 ↗
17. Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years10.1186/s12951-024-02900-y ↗
18. Imaging and monitoring HER2 expression in tumors during HER2 antibody-drug conjugate therapy utilizing a radiolabeled site-specific single-domain antibody probe: 68Ga-NODAGA-SNA004-GSC10.1021/acs.jmedchem.4c00857 ↗
19. Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors10.1093/oncolo/oyae168 ↗
20. Theranostic application of 64Cu/177Lu-labeled anti-Trop2 monoclonal antibody in pancreatic cancer tumor models10.1007/s00259-022-05954-y ↗
21. Preclinical Development and Comparison of [99mTc]Tc/[177Lu]Lu-Labeled Anti-Trop2 Fc-Fused Nanobodies as Pancreatic Cancer Theranostics10.1021/acs.molpharmaceut.5c01039 ↗
22. Preclinical evaluation of the theranostic potential of 89Zr/177Lu-labeled anti-TROP-2 antibody in triple-negative breast cancer model10.1186/s41181-023-00235-x ↗
23. Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody-drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer10.1007/s00259-025-07106-4 ↗
24. ImmunoPET imaging of Trop2 expression in bladder cancer using [64Cu]Cu-NOTA-Trodelvy10.1021/acs.molpharmaceut.5c00069 ↗
25. Preclinical evaluation of a Trop2-Targeted peptide probe for PET imaging of triple-negative breast cancer10.1021/acs.analchem.5c05242 ↗
26. De novo discovery and preclinical evaluation of a novel peptide radiotracer for PET imaging of TROP-2 in non-small cell lung cancer10.1016/j.bioorg.2025.109204 ↗
27. In silico design and preclinical evaluation of a novel Trop2-targeted peptide tracer for PET imaging of tumors10.1007/s11426-025-2856-2 ↗
28. ImmunoPET imaging of Trop2 expression in solid tumors with nanobody tracers10.1007/s00259-023-06454-3 ↗
29. ImmunoPET imaging of Trop2 in patients with solid tumours10.1038/s44321-024-00059-5 ↗
30. 68Ga-MY6349 PET/CT imaging to assess Trop2 expression in multiple types of cancer10.1172/JCI185408 ↗
31. Single-Domain antibody probe with low renal uptake for claudin 18.2-Targeted PET imaging of gastric cancer: preclinical and pilot clinical evaluations10.2967/jnumed.125.271704 ↗
32. Pilot study of a novel nanobody 68Ga-NODAGA-SNA006 for instant PET imaging of CD8+ T cells10.1007/s00259-022-05903-9 ↗
33. [68Ga]Ga-NOTA-T4 ImmunoPET imaging for evaluating TROP2 expression in patients with solid tumors10.1007/s00259-025-07326-8 ↗
34. Immuno-PET/CT imaging of Trop2 with [18F]AlF-RESCA-T4 Differentidtes Lung Cancel froc Inflammatiin
35. [99mTc]Tc-MY6349 Probe for Trop2-Targeted SPECT Imaging: From Pieclinicaf to pilot Clinical ptudy10.2967/jnumed.124.268564 ↗